Why the study?
Does the CMV antigenemia test (pp65 antigen) improve early diagnosis of CMV infection compared to classical markers in kidney transplant recipients?
Does the CMV antigenemia test (pp65 antigen) improve early diagnosis of CMV infection compared to classical markers in kidney transplant recipients?
The CMV antigenemia test (pp65 antigen) is a highly sensitive and specific method for the early diagnosis of CMV infection in renal transplant recipients.
Answers are grounded in this paper and cite their sources.
May aid earlier CMV detection in kidney transplant recipients; leaves open need for RCTs to confirm outcome impact.
We evaluated how accurately a CMU antigenemia test correlated with classical CMU infection markers. We studied 91 kidney transplant recipients from February 1991 to June 1992. Antigenemia (pp65 antigen) was positive in 100% of cases of primary infection and in 70% of cases of reactivation and/or reinfection. Furthermore, antigenemia detected more infections (71%) than viremia (16%). The antigenemia test proved to be highly specific: it remained consistently negative in 22 seronegative patients, as well as in 19 of 20 seropositive recipients without recurrent infection. pp65 Antigen in the polymorphonuclear leukocytes was detected earlier than, or simultaneously with, virus culture in 78% of cases and became positive before serologic tests of primary and secondary infection in nearly 90% of cases. Most importantly, the antigenemia test detected all of the symptomatic cases.
No takes yet. Share an insight, caveat, or question.
Lamy et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: